Erbulozole
Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.[1]
![]() | |
Clinical data | |
---|---|
Other names | Erbuzole |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H27N3O5S |
Molar mass | 469.56 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Synthesis
![](../I/m/Erbulozole_synthesis.png)
Erbulozole synthesis: Lednicer book 6 (Drugs of the Future citation).
gollark: !typerace 10
gollark: "Hello yes I like this particular polyhedron"
gollark: What's that ABOUT, exactly?
gollark: <@612084587740528640> void linux.
gollark: hi
References
- Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA (1993). "Phase I trial of erbulozole (R55104)". Anticancer Research. 13 (6B): 2389–91. PMID 8135472.
Other reading
- Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.